A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells
Author:
Funder
National Cancer Institute
National Natural Science Foundation of China
Natural Science Foundation of Guangdong Province
National Institutes of Health
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference67 articles.
1. Molecular portraits of human breast tumours;Perou;Nature,2000
2. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups;Curtis;Nature,2012
3. Comprehensive molecular portraits of human breast tumours;Nature,2012
4. Breast Cancer: Multiple Subtypes within a Tumor?;Yeo;Trends Cancer,2017
5. Breast cancer;Harbeck;Nat Rev Dis Primers,2019
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cocrystal@protein-anchoring nanococktail for combinatorially treating multidrug-resistant cancer;Acta Pharmaceutica Sinica B;2024-08
2. Activation of the PERK/eIF2α axis is a pivotal prerequisite of taxanes to cancer cell apoptosis and renders synergism to overcome paclitaxel resistance in breast cancer cells;Cancer Cell International;2024-07-17
3. Semisynthetic phytochemicals in cancer treatment: a medicinal chemistry perspective;RSC Medicinal Chemistry;2024
4. Nanoscale drug delivery systems for cancer therapy using paclitaxel— A review of challenges and latest progressions;Journal of Drug Delivery Science and Technology;2023-06
5. Recent advances in the strategic incorporation of fluorine into new-generation taxoid anticancer agents;Journal of Fluorine Chemistry;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3